Trials / Completed
CompletedNCT01455844
TRIal For Efficacy of Capre on hyperTriglyceridemiA
A Randomized, Placebo-controlled, Double-blind, Dose-ranging, Multi-centered Trial to Evaluate the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 387 (actual)
- Sponsor
- Grace Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether CaPre(TM), given at doses 1.0g or 2.0g for 12 weeks, has an effect on fasting plasma triglycerides in patients with mild to high hypertriglyceridemia as compared to a placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CaPre (TM) | CaPre™ 1.0g + Placebo 1.0g daily for 12 weeks. |
| OTHER | Placebo | 2.0g Placebo (Microcrystalline cellulose) daily for 12 weeks |
| DRUG | CaPre (TM) | CaPre™ 2.0g daily for 12 weeks |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2014-06-01
- Completion
- 2014-08-01
- First posted
- 2011-10-20
- Last updated
- 2014-08-22
Locations
38 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT01455844. Inclusion in this directory is not an endorsement.